ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1133

Exploring the Clinical Characteristics and Correlation with Corticosteroid Dependence in Polymyalgia Rheumatica (PMR) Patients: Insights from an Academic Center

William Rigby1, Todd Mackenzie2, Emily Campbell1, Joshua Skydel3, Bryan Savage1, Monica Dimambro2 and Vivekanand Tiwari1, 1Dartmouth Hitchcock Medical Center, Lebanon, NH, 2Dartmouth College, Hanover, NH, 3Dartmouth-Hitchcock Medical Center, Lebanon, NH

Meeting: ACR Convergence 2023

Keywords: corticosteroids, giant cell arteritis, Polymyalgia Rheumatica (PMR), quality of care

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1124–1154) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Polymyalgia rheumatica (PMR) treatment is primarily based on long-term corticosteroids, which results in significant toxicities. Studies1,2 have shown that patients with PMR are exposed to years of corticosteroid treatment. In a single academic center cohort, we found that 76% of patients remained on steroids at the end of two years.3 In a second cohort of PMR patients, we explored the baseline characteristics and established the success rate in discontinuing steroid treatment at years one and two after initiating the treatment.

Methods: A retrospective observational study was conducted using data collected from a rheumatology clinic at an academic Medical Center. We included patients with a primary diagnosis of PMR or PMR associated with Giant cell arteritis (GCA) and a minimum of 1-year follow-up. Patients with other rheumatological disorders were excluded. Out of 403 PMR charts reviewed from 2011 to 2021, 346 patients met the inclusion criteria.

Results: The mean age of the patient population was 71 years, with 59% being females and 41% males. Approximately 20% of the patients experienced an abrupt onset of symptoms. Among the PMR patients, 17.1% had a concurrent diagnosis of GCA, which usually developed alongside or after the PMR diagnosis. Only 2% of patients presented with Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE). At the beginning of treatment (T0), the mean prednisone dose was 24 mg daily. At one year (T1), it decreased to 6.4 mg, and at two years (T2), it further reduced to 4.3 mg daily. At the end of one year, 17.7% of patients had discontinued prednisone, while only 38% had achieved discontinuation by the end of two years. The majority of patients exhibited elevated markers of inflammation (ESR or CRP), with only 14.6% presenting with normal values initially. The only patient characteristic associated with successful discontinuation was the initial steroid dose. Multivariable logistic regression analysis showed that with each unit increase in the initial prednisone dose, the odds of successfully discontinuing prednisone at 12 months decreased by 3% (p = 0.034). However, the significance of this association was not sustained at the 24-month mark. No other baseline characteristics were associated with successful prednisone discontinuation.

Conclusion: The clinical course of PMR is characterized by prolonged corticosteroid use, with a discouraging rate of successful prednisone discontinuation. Our study validates previous observations3 and provides additional insights into the clinical characteristics of PMR patients. Similar to prior research4,5, our study demonstrates that the initial corticosteroid dosage predicts the likelihood of successful discontinuation. However, the significance of this association diminishes at the 24-month mark, highlighting the need for further investigation. We acknowledge the limitations of our retrospective study, including potential selection bias due to the inclusion of patients with only one year of follow-up. Nonetheless, these findings underscore the urgency for additional research to identify and incorporate alternative disease-modifying anti-rheumatic drugs (DMARDs) into the PMR treatment regimen.

Supporting image 1

Supporting image 2


Disclosures: W. Rigby: None; T. Mackenzie: None; E. Campbell: None; J. Skydel: None; B. Savage: None; M. Dimambro: None; V. Tiwari: None.

To cite this abstract in AMA style:

Rigby W, Mackenzie T, Campbell E, Skydel J, Savage B, Dimambro M, Tiwari V. Exploring the Clinical Characteristics and Correlation with Corticosteroid Dependence in Polymyalgia Rheumatica (PMR) Patients: Insights from an Academic Center [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/exploring-the-clinical-characteristics-and-correlation-with-corticosteroid-dependence-in-polymyalgia-rheumatica-pmr-patients-insights-from-an-academic-center/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/exploring-the-clinical-characteristics-and-correlation-with-corticosteroid-dependence-in-polymyalgia-rheumatica-pmr-patients-insights-from-an-academic-center/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology